CD4 and diabetic kidney disease: Li et al. indicated that compared with the use of irbesartan alone, combined with BLC could significantly improve the micro-inflammatory state and oxidative stress response of DKD patients, with reduce levels of TNF-α, CRP, ROS and advanced protein oxidation product (AOPPS), and increased CD4+ and CD4+/CD8+ levels to regulate immune disorders (Li Z. et al., 2019b).